Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445557 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks
A Phase 2 study, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT05445557 is a Phase 2 study that has completed, run by Raziel Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT05445557, a Phase 2 study, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
A total of 12 subjects will be injected with RZL-012 and placebo. Each of the subject's flanks will be randomized for each of the treatment. A total of 24 flanks will be randomized in the double blind phase. They will be monitored for safety and efficacy for 12 weeks. After codes opening, a second treatment cycle on the previously untreated contralateral flank will be done. Subjects will be monitored for safety and efficacy for additional 12 weeks.
Interventions
- DRUG Placebo
- DRUG RZL-012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2022-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05445557
The ClinicalTrials.gov registry entry for NCT05445557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raziel Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05445557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05445557 about?
NCT05445557 is a clinical study titled "Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks". A total of 12 subjects will be injected with RZL-012 and placebo. Each of the subject's flanks will be randomized for each of the treatment. A total of 24 flanks will be randomized in the double blind phase. They will be monitored for safety and efficacy for 12 weeks. After codes opening, a second t...
What is the current status of trial NCT05445557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-03-10. Estimated completion is 2022-11-10.
What interventions are being tested in trial NCT05445557?
The interventions under investigation include: Placebo (DRUG), RZL-012 (DRUG).
Who is sponsoring clinical trial NCT05445557?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.